Tue, December 19, 2023

Derek Archila Maintained (BPMC) at Buy with Increased Target to $115 on, Dec 19th, 2023

Derek Archila of Wells Fargo, Maintained "Blueprint Medicines Corporation" (BPMC) at Buy with Increased Target from $86 to $115 on, Dec 19th, 2023.

Derek has made no other calls on BPMC in the last 4 months.



There are 5 other peers that have a rating on BPMC. Out of the 5 peers that are also analyzing BPMC, 2 agree with Derek's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Michael Ulz of "Morgan Stanley" Maintained at Hold with Increased Target to $63 on, Friday, October 27th, 2023
  • Peter Lawson of "Barclays" Maintained at Hold with Increased Target to $58 on, Friday, October 27th, 2023


These are the ratings of the 3 analyists that currently disagree with Derek


  • Andrew Fein of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $85 on, Monday, December 11th, 2023
  • Matthew Biegler of "Oppenheimer" Upgraded from Hold to Buy and Held Target at $85 on, Friday, October 27th, 2023
  • Ami Fadia of "Needham" Maintained at Strong Buy with Increased Target to $74 on, Friday, October 27th, 2023